publication date: Jun. 20, 2014

Conversation With The Cancer Letter

What $34,000 per Patient Buys in Lung-MAP

The Cancer Letter asked David Wholley, director of the Foundation for the National Institutes of Health Biomarker Consortium, to explain the novel scientific and administrative structure of Lung-MAP.

Wholley spoke with Paul Goldberg, editor and publisher of The Cancer Letter.


Paul Goldberg:
Can we start with the financial map of this trial?

David Wholley: For the first five drugs that are going into the trial, NCI is putting in about $24 million, and companies are putting in about $55 million. This would cover the costs for all of the drugs to complete testing through phase III.

But that’s probably not the most useful way to think about how the trial is financed, because the number of patients varies per drug, not all the drugs will complete testing through phase III of course, and at least one of the drugs has additional tests that the company wants to have performed, costs that are outside the base protocol.

The best way to think about this really is that over five years, the infrastructure is designed to screen about 6,250 patients with the goal that 5,000 of them would actually go on trial. It’s going to do that at a cost of about $34,000 a patient who is enrolled, which includes the costs to screen patients.

The total cost to screen and treat all of these patients over the five years runs about $169 million. Out of the $34,000 per patient cost, NCI is paying about $9,000 a patient, and another $25,000 … Continue reading 40-25 Conversation with The Cancer Letter: FNIH’s David Wholley

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.